P546 Which are the optimal adalimumab trough levels associated with biological remission in patients with inflammatory bowel disease?
| Autor: | Francisco Rodríguez-Moranta, J Bas, E Santacana, K Serra, C Arajol, R. Rodríguez, Lorena Rodríguez-Alonso, Jordi Guardiola, Ariadna Padullés, F. Morandeira-Rego, Pau Gilabert, N Padullés |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
medicine.diagnostic_test business.industry Gastroenterology General Medicine medicine.disease Trough (economics) Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine Therapeutic drug monitoring 030220 oncology & carcinogenesis Internal medicine medicine Adalimumab 030211 gastroenterology & hepatology In patient business medicine.drug |
| Zdroj: | Journal of Crohn's and Colitis. 11:S358-S358 |
| ISSN: | 1876-4479 1873-9946 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|